VISTA Inhibitors Drugs Clinical Trials Report 2023

Tuesday, January 31, 2023 at 7:07am UTC

Delhi, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2023 Report Highlights:

  • Market Potential Of VISTA Inhibitors
  • Market Commercialization Assessment Scenario
  • Partnerships, Collaborations & Agreements
  • Global VISTA Inhibitors Clinical Pipeline By Biomarker, Indication, Company, Country & Phase
  • Global VISTA Inhibitors Market Dynamics
  • Insight On 15 Companies Involved In Development Of VISTA Inhibiting Drugs
  • Role Of VISTA As Inhibitory & Costimulatory Checkpoint

Download Report:

With evolution in the research and development domain and with help from technological advancements and researchers’ increasing knowledge, a number of proteins have been discovered to play central roles in development and progression of many diseases. Immune checkpoint proteins have especially come to light for their role in suppressing anti-cancer immune responses. The VISTA protein is one of the newest checkpoint proteins to be discovered which has showed potential in treating both cancer and inflammatory diseases because of its extraordinary properties that make it different from its fellow checkpoint proteins.

V-domain Ig suppressor of T cell activation, commonly known as VISTA, is an immune checkpoint protein which exerts both inhibitory and stimulatory effects on the immune system. Other identified immune checkpoints are only known to negatively regulate immune responses which is why the latter makes VISTA unique. Blocking its inhibitory functions has emerged as a hot approach in the treatment of cancer, while its immune system stimulatory functions have been explored widely in murine models.

Though its role in inflammatory diseases has been recognized, no agonists have been reported to be under development to escalate its inhibitory actions on the immune system. Cancer is a major cause of death globally which partly explains why researchers have leaned towards its inhibitory role in cancer for drug development. This can also be attributed to the years of success immune checkpoint inhibitors have shown in the market. Besides many drugs used in the treatment of inflammatory diseases have already created a niche for themselves in the market.

The relationship between VISTA and PD-L1 is also being researched right now. With varying expression from case to case, VISTA and PD-L1 simultaneously affect the immune system and the tumor microenvironment. It has been shown that PD-1/PDL-1 inhibition still has an effect on tumors that express VISTA, but the outcome is diverse because the routes for these proteins are distinct. Following this concept, a drug candidate called CA-170 was developed under a collaboration agreement between Aurigene and Curis. CA-170 is the first drug to enter clinical trials and is also the first and the only small molecule inhibitor designed to target both VISTA and PD-L1. Both CA-170 and its precursor AUNP-12 have displayed exceptional PK-PD correlation, upping the potential of CA-170 to become the first VISTA inhibitor in the global market. The candidate has already advanced to later stages in clinical trials being held in India to check the efficacy of the drug in the treatment of stage IV lung cancer patients in combination with standard chemotherapy.

Under addition to CA-170, other pharmaceutical firms with medication candidates in development include Sensei Biotherapeutics, Hummingbird Bioscience, Kineta, and PharmAbcine. Collaborations in research, development, and clinical settings have also been on the rise thanks to the introduction of VISTA inhibitors. In the first months of 2023, Sensei Biotherapeutics and the multinational pharmaceutical behemoth Regeneron announced their most recent partnership. Regeneron will provide its PD-1-directed monoclonal antibody Libtayo (cemiplimab) under the terms of this clinical supply agreement to help Sensei evaluate its SNS-101 VISTA inhibitor in the clinical setting as a combination. Additionally, reports indicate that Sensei is on track to submit an investigational new drug application for SNS-101 by no later than April 2023. Later this year, the study is planned to begin after regulatory approval.

VISTA can be seen on a number of tumor types, which increases the variety of cancer forms VISTA inhibition can be applied in. it can be said that the development of VISTA monoclonal antibodies with diverse immunological functions such as those with inhibitory or stimulatory effects have helped shape the path for future research studies. Possible treatment advantages as well as detailed knowledge of immune system homeostasis will result from mechanistic molecular comprehension of the functions for VISTA on the innate vs. adaptive immune system. Forthcoming studies on patients should focus on the unstratified signaling pathways of VISTA and other checkpoint proteins like PD-1 and its receptor PD-L1 in light of the present information on prognosis and their correlation with VISTA that has been discovered thus far.   


Neeraj Chawla
Kuick research
Research Head

Primary Logo